Nikhil Ananth is a Principal at F-Prime and invests across multiple subsectors including therapeutics, medical technology, research tools, and life science software & services. Since joining F-Prime in 2019, Nikhil has supported investments in several companies including Adela, Countable Labs, Ensoma, Galatea Bio, Invetx (acquired by Dechra), Ivenix (acquired by Fresenius Kabi), Metsera (NASDAQ: MTSR, acquired by Pfizer), and Rallybio (NASDAQ: RLYB), among others. Nikhil also works closely with the Eight Roads Ventures team to manage F-Prime’s healthcare investments in India.

Prior to joining F-Prime, Nikhil was an Associate at Audax Group in Boston, where he focused on private equity investments in healthcare and software. Nikhil is a graduate of the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where he received a B.A. in Biology and a B.S. in Economics from the Wharton School.